Biogen Historical Cash Flow
| BIIB Stock | USD 158.71 0.81 0.51% |
Analysis of Biogen cash flow over time is an excellent tool to project Biogen Inc future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 3.6 B or Depreciation of 348 M as it is a great indicator of Biogen ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Biogen Inc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Biogen Inc is a good buy for the upcoming year.
Biogen |
About Biogen Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Biogen balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Biogen's non-liquid assets can be easily converted into cash.
Biogen Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Biogen Inc to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Biogen operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Biogen Inc financial statement analysis. It represents the amount of money remaining after all of Biogen Inc operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most accounts from Biogen's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Biogen Inc current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. At present, Biogen's Free Cash Flow is projected to increase significantly based on the last few years of reporting. The current year's Begin Period Cash Flow is expected to grow to about 3.6 B, whereas Change In Cash is projected to grow to (2.3 B).
Biogen cash flow statement Correlations
Click cells to compare fundamentals
Biogen Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Biogen cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 1.7B | (1.6B) | 930.2M | 1.2B | (2.4B) | (2.3B) | |
| Free Cash Flow | 6.4B | 3.7B | 3.3B | 1.1B | 1.2B | 1.3B | |
| Change In Working Capital | 199.3M | (187.2M) | (145.5M) | (890.3M) | (648.7M) | (616.3M) | |
| Begin Period Cash Flow | 1.2B | 2.9B | 1.3B | 2.3B | 3.4B | 3.6B | |
| Other Cashflows From Financing Activities | 7.9M | 2.9B | (114.8M) | 4.9M | (38M) | (36.1M) | |
| Depreciation | 680.6M | 457.2M | 487.7M | 518.4M | 494.8M | 348.0M | |
| Other Non Cash Items | 60.8M | (448M) | 1.8B | (1.3B) | 581.2M | 610.3M | |
| Dividends Paid | 302.7M | 36.4M | 4.6M | 700K | 805K | 764.8K | |
| Capital Expenditures | 669.5M | 551.8M | 294.9M | 243.2M | 311.4M | 429.3M | |
| Total Cash From Operating Activities | 7.1B | 4.2B | 3.6B | 1.4B | 1.5B | 1.7B | |
| Change To Account Receivables | 68.8M | 2.8M | 324.8M | (203.4M) | 61.3M | 64.4M | |
| Net Income | 5.9B | 4.1B | 1.7B | 3.0B | 1.2B | 1.3B | |
| Total Cash From Financing Activities | (5.9B) | (5.3B) | (2.1B) | (1.8B) | 149.3M | 156.8M | |
| End Period Cash Flow | 2.9B | 1.3B | 2.3B | 3.4B | 1.0B | 800.3M | |
| Sale Purchase Of Stock | (4.4B) | (5.9B) | (6.7B) | (1.8B) | (750M) | 0.0 | |
| Change To Inventory | (19.2M) | (316.3M) | (462.4M) | (320.2M) | (130.9M) | (137.4M) | |
| Change To Liabilities | 213M | (50.4M) | (9.1M) | (347.7M) | (399.9M) | (379.9M) | |
| Stock Based Compensation | 182.3M | 198.3M | 238.6M | 254.1M | 264.2M | 195.9M | |
| Total Cashflows From Investing Activities | 470.5M | (608.6M) | (563.7M) | 1.6B | 1.8B | 1.9B | |
| Other Cashflows From Investing Activities | (248.7M) | (153.9M) | 4.2M | 604.1M | 543.7M | 570.9M | |
| Investments | 1.2B | (29.9M) | (309.8M) | 1.6B | (4.1B) | (3.9B) | |
| Change Receivables | 68.8M | 2.8M | 324.8M | (203.4M) | (233.9M) | (245.6M) | |
| Cash And Cash Equivalents Changes | 1.7B | (1.7B) | 990M | 1.2B | 1.4B | 1.5B | |
| Cash Flows Other Operating | (8M) | (597.6M) | 828M | 246.9M | 283.9M | 298.1M | |
| Change To Netincome | 254.9M | 673.6M | 743.3M | (1.5B) | (1.3B) | (1.3B) | |
| Change To Operating Activities | 133.6M | 193.8M | (238.7M) | (224.4M) | (202.0M) | (191.9M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Biogen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biogen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biogen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biogen Inc Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biogen. If investors know Biogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.02) | Earnings Share 11.05 | Revenue Per Share 66.122 | Quarterly Revenue Growth (0.03) | Return On Assets 0.0499 |
The market value of Biogen Inc is measured differently than its book value, which is the value of Biogen that is recorded on the company's balance sheet. Investors also form their own opinion of Biogen's value that differs from its market value or its book value, called intrinsic value, which is Biogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biogen's market value can be influenced by many factors that don't directly affect Biogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.